^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    azacitidine

    i
    Other names: U-18496, Aza-C, NS 17, NS-17, Aza C, NSC-102816
    Company:
    Generic mfg.
    Drug class:
    DNMT inhibitor
    Related drugs:
    1d
    Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=20, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    azacitidine • Orencia (abatacept)
    1d
    A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (clinicaltrials.gov)
    P2, N=160, Recruiting, Chinese PLA General Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • aclarubicin
    1d
    WT1 mRNA in peripheral blood enables early prognostic stratification in AML patients receiving venetoclax and azacitidine therapy. (PubMed, Ann Hematol)
    Moreover, achieving PB WT1 mRNA negativity-regardless of whether this occurred early or later in the therapy།was consistently associated with superior OS and PFS. These findings suggest that PB WT1 mRNA is a sensitive and reliable biomarker for predicting treatment response and long-term outcomes in patients with AML receiving VEN/AZA.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • WT1 (WT1 Transcription Factor)
    |
    Venclexta (venetoclax) • azacitidine
    1d
    Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. (PubMed, Cell Stem Cell)
    LSC subtyping improves genetic risk stratification and provides subtype-specific therapies: venetoclax-resistant MEP-LSCs respond to BCL-xL inhibitors, whereas MoDe-LSCs are sensitive to MEK1/2 inhibition. Our findings reveal four distinct LSC types with unique vulnerabilities and propose biomarker-guided treatment strategies that complement genetic profiling to overcome venetoclax resistance.
    Journal • IO biomarker
    |
    BCL2L1 (BCL2-like 1)
    |
    Venclexta (venetoclax) • azacitidine
    2d
    A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. (clinicaltrials.gov)
    P1, N=14, Completed, Novartis Pharmaceuticals | Terminated --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • siremadlin (HDM201)
    2d
    Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New trial
    |
    Venclexta (venetoclax) • sorafenib • azacitidine • cyclophosphamide • fludarabine IV
    2d
    A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    azacitidine • Blincyto (blinatumomab) • sonrotoclax (BGB-11417)
    3d
    LYT-200-2022-02: A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1, N=101, Completed, PureTech | Recruiting --> Completed
    Trial completion
    |
    Venclexta (venetoclax) • azacitidine • decitabine • LYT-200
    3d
    Verona: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P3, N=531, Active, not recruiting, AbbVie | Trial completion date: Mar 2026 --> Jul 2027 | Trial primary completion date: Mar 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine
    3d
    VENP-A-QUI: A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patients ineligible for standard induction chemotherapy (2025-522979-29-00)
    P2/3, N=350, Recruiting, Fundacion PETHEMA | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib)
    4d
    Case Report: Use of mirvetuximab soravtansine in a patient with platinum-resistant ovarian cancer and concomitant PARP-inhibitor-related myelodysplastic syndrome. (PubMed, Front Oncol)
    We report a 65-year-old patient with heavily pretreated, FRα-positive ovarian cancer who developed therapy-related myelodysplastic syndrome with increased blasts (MDS-IB2, DNMT3A-mutated) during therapy with MIRV in combination with carboplatin having received prior PARPi maintenance therapy. This case demonstrates that MIRV can be safely and effectively administered alongside azacitidine, providing clinically meaningful tumor control without compromising hematologic outcomes. These findings support the concurrent management of ovarian cancer and therapy-related MDS as a viable and underutilized treatment approach in a highly challenging clinical setting.
    Journal • PARP Biomarker • Platinum resistant
    |
    DNMT3A (DNA methyltransferase 1) • FOLR1 ( Folate receptor alpha )
    |
    carboplatin • azacitidine • Elahere (mirvetuximab soravtansine-gynx)
    5d
    Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jul 2026 --> Oct 2026
    Trial primary completion date
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NUP214 (Nucleoporin 214) • KAT6A (Lysine Acetyltransferase 6A) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    NPM1 mutation • KMT2A rearrangement
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • methotrexate • Revuforj (revumenib)